## TITLE

## LONG-TERM EFFICACY AND SAFETY OF MONOTHERAPY VERSUS COMBINATION THERAPY IN SYSTEMIC SCLEROSIS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION: A retrospective cohort study from the nationwide Spanish Scleroderma Registry (RESCLE)

Melani Pestaña-Fernández (1), Manuel Rubio-Rivas (1), Carles Tolosa Vilella (2), Alfredo Guillén del Castillo (3), Mayka Freire (4), Jose Antonio Vargas Hitos (5), Jose Antonio Todolí Parra (6), Mónica Rodríguez Carballeira (7), Adela Marín Ballvé (8), Gerard Espinosa (9), Dolores Colunga Argüelles (10), Norberto Ortego-Centeno (11), Luis Trapiella Martínez (12), Cristina Carbonell Muñoz (13), Xavier Pla Salas (14), Isabel Perales Fraile (15), Xavier Corbella (1,16), Vicent Fonollosa Pla (3), Carmen Pilar Simeón Aznar (3) on behalf of RESCLE investigators, Autoimmune Diseases Study Group (GEAS).
*See Appendix for Members of the RESCLE Registry
(1) Autoimmune Diseases Unit. Department of Internal Medicine. Bellvitge University Hospital. L'Hospitalet de Llobregat, Barcelona, Spain.
(2) Department of Internal Medicine. Corporación Sanitaria Universitaria Parc Taulí. Sabadell, Barcelona, Spain.
(3) Unit of Autoimmune Diseases, Department of Internal Medicine. Hospital Universitario Vall d'Hebron. Barcelona, Spain.
(4) Unit of Systemic Autoimmune Diseases and Thrombosis. Department of Internal Medicine. Complejo Hospitalario Universitario de Vigo. Vigo, Pontevedra, Spain.
(5) Department of Internal Medicine. Hospital Universitario Virgen de las Nieves. Granada, Spain.
(6) Department of Internal Medicine. Hospital Universitario y Politécnico La Fe. Valencia, Spain.
(7) Department of Internal Medicine. Hospital Universitario Mútua Terrassa. Terrassa, Barcelona, Spain.
(8) Unit of Autoimmune Diseases, Department of Internal Medicine. Hospital Clínico Universitario Lozano Blesa. Zaragoza, Spain.
(9) Department of Systemic Autoimmune Diseases, Clinical Institute of Medicine and Dermatology. Hospital Universitario Clinic. Barcelona, Spain.
(10) Department of Internal Medicine. Hospital Universitario Central de Asturias. Oviedo, Asturias, Spain.
(11) Unit of Systemic Autoimmune Diseases, Department of Internal Medicine. Hospital Campus de la Salud, Complejo Universitario de Granada. Granada, Spain.
(12) Unit of Systemic Autoimmune Diseases, Department of Internal Medicine. Hospital de Cabueñes. Gijón, Asturias, Spain.
(13) Department of Internal Medicine, Complejo Asistencial Universitario de Salamanca, Spain.
(14) Unit of Systemic Autoimmune Diseases, Department of Internal Medicine. Consorci Hospitalari de Vic. Vic, Barcelona, Spain.
(15) Department of Internal Medicine. Hospital Universitario Rey Juan Carlos. Móstoles, Madrid, Spain.
(16) Faculty of Medicine and Health Sciences. Universitat Internacional de Catalunya,Barcelona,Spain.

KEY INDEXING TERMS: Systemic sclerosis; Pulmonary arterial hypertension; Survival analysis.

## CORRESPONDING AUTHOR:

Melani Pestaña-Fernández MD; Bellvitge University Hospital, Department of Internal Medicine, Feixa Llarga s/n 08907 L'Hospitalet de Llobregat Barcelona (Spain); Melani.Pestana@sanitatintegral.org

## RUNNING HEAD

Monotherapy versus combination


#### Abstract

Objective: Monotherapy is an option as first line therapy for pulmonary arterial hypertension (PAH). However, combination therapy is a beneficial alternative. Our objective was to evaluate efficacy of monotherapy vs. combination therapy in Systemic Sclerosis (SSc)-associated PAH patients.

Methods: All patients with SSc-associated PAH from the Spanish Scleroderma Registry (RESCLE) were reviewed. Patients were split up in three groups: monotherapy vs. sequential combination vs. upfront combination. Primary endpoint was death from any cause at 1,3 and 5 years from PAH diagnosis.

Results: 76 patients (4.2\%) out of 1817 had SSc-related PAH. 34 patients (45\%) were receiving monotherapy [ERA (22, 29\%) or PDE5 inhibitors (12, $16 \%)$ ], 25 (33\%) sequential combination, and 17 (22\%) upfront combination. A lower FVC/DLco in the sequential combination group was reported ( $2.9 \pm 1.1$ vs. $1.8 \pm 0.4$ vs. $2.3 \pm 0.8, p=0.085)$ and also a higher mPAP in combination groups ( $37.2 \pm 8.7 \mathrm{mmHg}$ vs. $40.8 \pm 8.8$ vs. $46 \pm 15.9, \mathrm{p}=0.026$ ) at baseline. Treatment regimen ( $p=0.017$ ) and functional class ( $p=0.007$ ) were found independent predictors of mortality. Sequential combination was found an independent protective factor $[\mathrm{HR}=0.11(95 \% \mathrm{Cl} 0.03-0.51), \mathrm{p}=0.004]$, while upfront combination showed a trend $[\mathrm{HR}=0.68(95 \% \mathrm{Cl} 0.23-1.97), \mathrm{p}=0.476]$. Survival from PAH diagnosis among monotherapy, sequential and upfront combination groups was: $78 \%$ vs. $95.8 \%$ vs. $94.1 \%$ at 1 year, $40.7 \%$ vs. $81.5 \%$ vs. $51.8 \%$ at 3 years and $31.6 \%$ vs. $56.5 \%$ vs. $34.5 \%$ at 5 years ( $p=0.007$ ). Side effects were not significantly different among groups.


Conclusions: Combination sequential therapy improved survival in our cohort.


#### Abstract

Abbreviations: SSc, systemic sclerosis; CTD, connective tissue disease; ILD, interstitial lung disease; PAH, pulmonary arterial hypertension; SRC, scleroderma renal crisis; IPAH/FPAH, idiopathic or familiar pulmonary arterial hypertension; WHO, World Health Organization; ERA, endothelin receptor antagonist; PDE5, phosphodiesterase-5; RESCLE, Spanish Scleroderma Registry; GEAS, Autoimmune Diseases Working Group; SEMI, Spanish Society of Internal Medicine; ACR, American College of Rheumatology; EULAR, European League Against Rheumatism; RHC, right heart catheterization; mPAP, mean pulmonary arterial pressure; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; NYHA, New York Heart Association; SD, standard deviation; ANOVA, analysis of variance; FVC, forced vital capacity; DLco, diffusing capacity of the lung for carbon monoxide; HR, hazard ratio; 6MWD, 6-minute walk distance; NT-proBNP, N-terminal pro b-type natriuretic peptide; TRV, tricuspid regurgitation velocity; sPAP, systolic pulmonary arterial pressure; TAPSE, tricuspid annular plane systolic excursion; FEV1, forced expiratory volume during the first second; ATA, antitopoisomerase I antibody; ACA, anti-centromere antibody; anti-RNA pol III, antiRNA polymerase III antibody; Anti-RNP, anti-ribonucleoprotein antibody.


## INTRODUCTION

Systemic sclerosis (SSc) is a connective tissue disease (CTD) of unknown origin. PAH is one of the most devastating complications, with a prevalence of $12-13 \%^{1-5}$. Left untreated, it leads to right ventricular failure and death. Its prognosis is worse than idiopathic/familial PAH (IPAH/FPAH) and other CTD-related PAH, being one of the main SSc-related causes of death ${ }^{6-8}$. SSc-related PAH survival has improved since the 80 's due to better disease knowledge, screening programmes and emerging therapies ${ }^{9-13}$. However, mortality is still high.

Monotherapy remains an option for PAH treatment ${ }^{14-16}$ recommended in guidelines ${ }^{17}$ as first-line therapy for World Health Organization (WHO) functional class (FC) II-III patients, with the same grade of evidence and recommendation (IA-IB) for endothelin receptor antagonists (ERA) and phosphodiesterase-5 (PDE5) inhibitors.

Combination therapy, targeting several of the main pathways that contribute to physiopathology of PAH (endothelin-1, prostacyclin and nitric oxide), is gaining evidence. Although in guidelines ${ }^{17}$ the grade of evidence and recommendation for combination therapy (IB) is the same as monotherapy, recent reports, including the AMBITION trial ${ }^{18}$ and its post-hoc analysis ${ }^{19}$ focused on CTD-PAH patients, suggest combination therapy as a better option to treat PAH, demonstrating its superiority in terms of morbimortality.

Our study was designed to evaluate the long-term efficacy and safety of combination therapy with PDE5 inhibitors and ERA versus monotherapy in a
large Spanish nationwide SSc-related PAH cohort. Moreover, mortality's impact was compared between different treatment regimens.

## MATERIALS AND METHODS

## Study design

This was a retrospective cohort study. Data were obtained from the Spanish Scleroderma Registry (RESCLE), a project of the Autoimmune Diseases Working Group (GEAS) within the Spanish Society of Internal Medicine (SEMI), which includes patients with SSc who fulfilled the 2013 ACR/EULAR criteria and/or the modified criteria proposed by LeRoy and Medsger in 1988 to avoid the possible missing of patients with scleroderma sine scleroderma or limited cutaneous systemic sclerosis who could not fulfill the 2013 ACR criteria. Data were collected retrospectively until 2006 and prospectively onwards. Thirty hospitals nationwide participated in the registry and 1817 patients were recorded. All participant centers obtained local Ethics Committee approval. We received ethics board approval of our institution (Bellvitge University Hospital, Barcelona, Spain) as well (ref. PR126/13).

Inclusion criteria were SSc-patients aged 18 years or more, with a diagnosis of PAH by right heart catheterization (RHC) with a mean pulmonary arterial pressure (mPAP) of $\geq 25 \mathrm{mmHg}$, a pulmonary capillary wedge pressure (PCWP) of $\leq 15 \mathrm{mmHg}$ and a pulmonary vascular resistance (PVR) of $>3$ Wood units, without ILD or with moderate ILD defined by FVC >60\% and not significant interstitial pattern on HRCT. Ongoing treatment with prostanoids was the only exclusion criterion. Patients gave informed consent to participate in the

RESCLE database. All centers included in the registry received their ethics board approval.

The patient population was split up in three groups according to treatment regimen: a) monotherapy with ARE or PDE5 inhibitors; b) sequential combination therapy, defined by $\geq 12$ weeks between initiation of first and second drug; c) upfront combination therapy, defined by $<12$ weeks between first and second drug. Cutting-point of 12 weeks was used in accordance with guidelines recommendations of reassessment ${ }^{17}$ and because of the design of most trials with monotherapy, which evaluate results at 12 weeks in order to decide effectiveness of treatment or whether escalating treatment is needed ${ }^{14-}$ ${ }^{16}$. Furthermore, in the recently published AMBITION trial, full doses of an upfront combination therapy with ambrisentan plus tadalafil were achieved in 8 weeks, so 12 weeks seemed an adequate limit to classify retrospectively upfront combination therapies as well ${ }^{18}$.

Clinical and laboratory data among groups were compared, including demographic data, age at which the first digital ulcer appeared, time from SSc diagnosis, time from first SSc symptom, SSc disease subtype, NYHA FC, visceral involvement, antibody profile, pulmonary functional tests (PFT), echocardiography measures and hemodynamic parameters in RHC.

## Outcomes

Primary endpoint was death from any cause at 1,3 , and 5 years from SSc-related PAH diagnosis. The cause of death was recorded and compared among the three different treatment groups. Additionally, side effects attributable to medication were collected and compared.

Downloaded on April 9, 2024 from www.jrheum.org

## Statistical analyses

All data were presented as absolute number and percentage for categorical variables and mean $\pm$ standard deviation (SD) for quantitative variables. Categorical variables were analyzed using Chi-square test and quantitative variables were analyzed with the analysis of variance (ANOVA). The Bonferroni's correction was applied for multiple comparisons among categorical variables. A univariate and multivariate Cox's proportional hazards model was performed in order to evaluate risk factors associated to mortality. Differences in mortality depending on the treatment prescribed were graphically shown by using Kaplan-Meier curves with their log-rank test. A p-value $<0.05$ was considered statistically significant.

No loss to follow-up was reported.

## RESULTS

Seventy-six patients with SSc-related PAH treated with ARE, PDE5 inhibitors or both were identified among 1817 SSc-patients of the RESCLE database, diagnosed between 2002 to 2016, except form one case diagnosed in 1997. Of those, 34 (45\%) were receiving monotherapy with ERA (22 patients, 29\%) or PDE5 inhibitors (12 patients, 16\%). Sequential combination therapy was given to 25 patients (33\%) and upfront combination therapy was initiated in 17 patients (22\%).

## General data among groups

Out of the 76 patients included, 69 (91\%) fulfilled the 2013 ACR criteria and the remaining 7 (9\%) fulfilled the 1988 LeRoy and Medsger criteria.

In all SSc-related PAH groups, either under monotherapy, sequential or upfront combination therapy, most patients were female [28 patients (82\%) vs. 23 (92\%) vs. 14 ( $82 \%$ ), $p=0.532$ ]. The study did not find differences in smoking behavior: current smokers 1 patient (3\%) vs. 2 ( $8.3 \%$ ) vs. 1 ( $6.7 \%$ ) ( $p=0.674$ ); former smokers 6 patients (18\%) vs. 4 (17\%) vs. 4 (27\%) ( $p=0.722$ ); and never smokers 26 patients (79\%) vs. 18 (75\%) vs. 10 (67\%), p=0.668. The age at onset of SSc was around 50 years-old ( $48.5 \pm 14.9$ years-old vs. $51.7 \pm 15$ vs. $48 \pm 15.8, p=0.694$ ) and the age at diagnosis of SSc close to 60 years-old ( $58.9 \pm 15.6$ years-old vs. $59.6 \pm 14.9$ vs. $57.7 \pm 13.4, \mathrm{p}=0.927$ ). Thus, the delay from the onset of the disease to the time of diagnosis was shorter in the sequential combination therapy group but without reaching statistical significance ( $11.8 \pm 12.6$ years vs. $5.8 \pm 9.8$ vs. $10.3 \pm 17.2, p=0.277$ ). The mean follow-up from the first symptom of SSc was $20.9 \pm 12.5$ years vs. $16.9 \pm 10.3$ vs. $17.7 \pm 15.9$ ( $p=0.511$ ) and the mean follow-up from the diagnosis of SSc was $9.8 \pm 8.3$ years vs. $9.7 \pm 7.4$ vs. $8.5 \pm 7.8(p=0.851)$ for monotherapy vs. sequential combination therapy vs. upfront combination therapy respectively. Regarding to PAH, the time from first SSc symptom until definitive PAH diagnosis was $19.5 \pm 12.8$ years vs. $11.6 \pm 11.7$ vs. $16.6 \pm 16.4(p=0.157)$ with statistically significant results comparing monotherapy with sequential combination ( $p=0.040$ ). More than $90 \%$ of patients met the 2013 ACR criteria [ 26 patients ( $93 \%$ ) vs. 22 ( $96 \%$ ) vs. 14 (100\%), p=0.581)]. No differences among groups were found according to the SSc subset. They were classified as IcSSc in 22 patients (65\%) vs. 16 (64\%) vs. 9 (56\%) ( $p=0.835$ ), dcSSc in 6 patients (18\%) vs. $5(20 \%)$ vs. $4(25 \%)(p=0.832)$ and sine scleroderma in 6 patients ( $18 \%$ ) vs.

4 (16\%) vs. 3 (19\%) ( $p=0.973$ ) for monotherapy, sequential combination and upfront combination therapy respectively.

Features among groups showed no differences (Table 1), related to serologic profile, capillaroscopy and visceral involvement, with the exception of pericardial involvement, which was more present in the upfront combination therapy group. The Bonferroni's correction confirmed statistical significance in pericardial involvement between upfront combination vs. monotherapy and sequential combination. Although it did not reach statistical significance, the percentage of ILD was different between groups, with $58 \%$ vs. $80 \%$ vs. $76.4 \%$ for monotherapy, sequential combination and upfront therapy respectively. Of those, the majority of patients had moderate ILD as defined earlier, with $55 \%$ vs. $70 \%$ vs. $58 \%$ for monotherapy, sequential combination and upfront therapy respectively.

## Functional status among groups at baseline

FC among groups at baseline, PFT, echocardiography and RHC findings are shown in table 2. It was noteworthy that a lower \%forced vital capacity/\%diffusing capacity of the lung for carbon monoxide ratio (\%FVC/\%DLco) was present in the sequential combination therapy group ( $2.9 \pm 1.1$ vs. $1.8 \pm 0.4$ vs. $2.3 \pm 0.8, \mathrm{p}=0.085$ ) and also a worse mPAP in both sequential and upfront combination therapy groups $(37.2 \pm 8.7 \mathrm{mmHg}$ vs. $40.8 \pm 8.8$ vs. $46 \pm 15.9, \mathrm{p}=0.026$ ). The Bonferroni's correction confirmed statistical significance in mPAP between upfront combination vs. monotherapy.

## Risk factors of mortality

In our univariate study, the prescribed treatment regimen, FC class at PAH diagnosis, \%FVC/\%DLco ratio and the change in the tricuspid regurgitation velocity (TRV) were considered risk factors of mortality (table 3).

After a multivariate analysis, the prescribed treatment regimen ( $p=0.017$ ) and FC at baseline ( $p=0.007$ ) were found independent predictors for long-term mortality (table 3). Taking monotherapy as reference treatment, sequential combination therapy was found to be a protective factor $[\mathrm{HR}=0.11(95 \% \mathrm{Cl} 0.03-$ 0.51), $p=0.004$ ] and upfront combination therapy showed a tendency of protection, without reaching statistical significance $[\mathrm{HR}=0.68$ ( $95 \% \mathrm{Cl} 0.23-1.97$ ), $\mathrm{p}=0.476]$.

## Survival and causes of death among groups

Long-term survival rates from diagnosis of SSc-related PAH among groups for monotherapy, sequential combination and upfront combination were, respectively, as follows: $78 \%$ vs. $95.8 \%$ vs. $94.1 \%$ at 1 year, $40.7 \%$ vs. $81.5 \%$ vs. $51.8 \%$ at 3 years and $31.6 \%$ vs. $56.5 \%$ vs. $34.5 \%$ at 5 years (log-rank test $\mathrm{p}=0.007$ ). Data of surviuval and patients at risk are shown in table 4 and Kaplan-Meier curves are shown in Figure 1.

Twenty-six patients (34.2\%) died during the follow-up. The causes of mortality among groups are shown in table 5. Death secondary to SSc-related PAH was the main cause of death in all groups [8 patients (47.1\%) vs. 2 (50\%) vs. 3 ( $60 \%$ ), $\mathrm{p}=0.749$ ].

## Side effects among groups

Side effects were not significantly different among groups [10 patients ( $29 \%$ ) vs. $8(32 \%)$ vs. $2(12 \%), \mathrm{p}=0.295]$. Most frequent side effects were as follows: edema, anemia, hepatotoxicity, arterial hypotension and headache attributed to AREs and rash, headache and hepatotoxicity due to PDE5 inhibitors.

## DISCUSSION

In our study, we evaluated long-term efficacy and safety of monotherapy versus combination therapy for PAH in a large Spanish SSc-patient cohort. Results showed better long-term survival rates for the overall combination therapy groups. Moreover, sequential combination therapy showed superiority against monotherapy as a long-term protective factor in such population, while upfront combination therapy showed a tendency of protection without reaching statistical significance. Although more drugs were used in combination therapy groups, no safety differences were found between treatment regimens.

Results from previous studies reporting SSc-related PAH survival from PAH diagnosis are heterogeneous in regard to NHYA FC, PAH specific regimens used, inclusion of incident or prevalent patients and inclusion of some degree of ILD. Mukerjee et al. ${ }^{20}$ conducted a prospective study including 722 patients with PAH FC III-IV diagnosed by RHC between 1998 and 2002, including 79 SSc-associated PAH patients, with survival at 1 and 3 years of $81 \%$ and $56 \%$. Williams et al. demonstrated better survival since introduction of Bosentan comparing two cohorts of SSc-associated PAH patients in FC III-IV, without significant ILD, showing 1 and 2 year survival of $68 \%$ and $47 \%$ in the
historical cohort (before 2002) and $81 \%$ and $71 \%$ in the contemporary cohort ${ }^{12}$. Fisher et al. reported a 1 and 3 year-survival of $87.7 \%$ and $48.9 \%$ in 50 patients with SSc-associated PAH without ILD, collected retrospectively from 2000 to 200521. In 2009, Condliffe et al. reported a 1, 3 and 5 year survival of $78 \%, 47 \%$ and $23 \%$ in a cohort of 429 CTD-associated PAH with 259 SSc-associated PAH, including patients with ILD and almost $30 \%$ of patients with combined therapy between 2001 and 200622. The 1 and 3 -year survival $86 \%$ and $65 \%$ from the multicentric retrospective study of 78 French patients with SScassociated PAH without significant ILD, was due to an early diagnosis by a screening program ${ }^{23}$. Survival with first line bosentan, followed or not by the addition of sildenafil or prostanoids, was $80 \%$ and $51 \%$ at 1 and 3 years in a long term outcome study published in 2010, which included 49 SSc-PAH patients, including those with ILD ${ }^{24}$. PHAROS cohort started in 2006, with 131 incident SSc-associated PAH patients without ILD, with 56 patients in FC I-II, showed $93 \%$ and $75 \%$ of survival, at 1 and 3 -years from PAH diagnosis, with $90 \%$ of patients receiving monotherapy ${ }^{25}$. Finally, in the contemporary REVEAL registry ${ }^{26}$ with 2749 PAH patients without significant ILD, including 504 SSc patients, showed a 5 -year survival of $39.6 \%$ in incident subjects vs. $46.2 \%$ in prevalent ones.

In our study, which includes patients mainly diagnosed from 2002 to 2016, 1, 3 and 5 -year survival with monotherapy was $78 \%, 40.7 \%$ and $31.6 \%$. Results are difficult to compare, but our survival could have been worse than others since most studies not only analyze survival with monotherapy, but include a variable percentage of sequential combination at reassessment, and because of the inclusion of moderate ILD.

Interestingly, studies evaluating sequential combination therapy showed similar results to ours in survival at 1, 3 and 5 years ( $95.8 \%, 81.5 \%$ and $56.5 \%$ ). In 2005, Hoeper et al. analyzed overall survival in an uncontrolled prospective study with goal-oriented therapy in 123 PAH patients ( $72 \%$ IPAH, 12\%, CTDPAH) that started bosentan and added sildenafil if monotherapy failed, a 1, 2 and 3 year survival of $93.3 \%, 88.3 \%$ and $83.9 \%^{27}$. Our study only included SSc-PAH patients, which are known to have a worse prognosis, so our results could be interpreted as better outcomes. Fox et al. meta-analysis in 2011 concluded that combination therapy improved 6-minute walk distance (6MWD) but did not decrease mortality, hospital admissions due to PAH, and the need of escalation therapy ${ }^{28}$. In the SERAPHIN study published in 2013, which included 742 PAH patients with $30.5 \%$ of CTD-PAH, macitentan significantly reduced a combined endpoint of morbimortality, also in patients with background therapy with PDE5 inhibitors ( $60 \%$ of the sample), indirectly showing that combination of ERA and PDE5 inhibitors had better outcomes than monotherapy ${ }^{29}$. In 2015, Dardi et al. conducted a retrospective study with 195 patients with sequential combination with sildenafil and bosentan ${ }^{30}$, with survival rates at 1,3 and 5 years similar to ours $(91 \%, 69 \%, 59 \%)$ but including only 29 CTD-PAH with a worse survival in this subgroup. On the other hand, COMPASS-2, failed to demonstrate superiority of sequential combination with sildenafil and bosentan, in 334 patients ( 88 with CTD-PAH) in delaying time until the first morbimortality event. The meta-analysis of Lajoie et al. ${ }^{32}$ in 2016 showed lower risk of clinical worsening with combination therapy with RR $0.65(95 \% \mathrm{Cl} 0.58-0.72)$ and Fox et al. ${ }^{33}$ meta-analysis found a reduction of $38 \%$ in clinical worsening but without reduction in mortality. Other combination sequential therapies including
prostacyclins ${ }^{34}$ and soluble guanylate-cyclase stimulators and triple combination therapy ${ }^{35}$ have shown promising outcomes.

Regarding upfront combination therapy, in $2004{ }^{36}$ the BREATHE-2 study compared epoprostenol plus bosentan vs. epoprostenol plus placebo, observing a non-significant decrease in total pulmonary resistance in the combination group, including only 5 SSc-associated PAH patients. In 2016, the AMBITON trial demonstrated a reduction of $50 \%$ in a morbimortality endpoint with ambrisentan plus tadalafil in 500 group1-PAH patients. In the post-hoc analysis of 187 CT-PAH patients, a reduction of $56 \%$ in morbimortality was found in the 118 SSc-associated PAH subset ${ }^{19}$.

In our study, upfront combination showed better results than monotherapy in mortality alone, but did not reach statistical significance.

The inclusion of patients with moderate ILD has to be taken in account. In the meta-analysis of Lefèvre ${ }^{37}$, survival for isolated PAH at 1,2 and 3 years was $82 \%, 67 \%$ and $56 \%$ respectively and for PAH-related ILD (defined as significant ILD in HRCT plus FVC or TLC around $60-70 \%$, or functional tests alone with FVC or TLC <60-70\%) survival was $75 \%, 48 \%$ and $35 \%$ respectively. It is important to point out that our study population had a remarkable percentage of ILD, as shown before, mainly moderate with FVC $>60 \%$, so we could compare our cohort with the isolated SSc-PAH and even so, better survival was found in the combination group, which was the one with higher percentage of ILD although not statistically significant. This supports the fact that SSc-PAH patients benefit from combination therapy compared to monotherapy, even with a mild to moderate degree of ILD. In fact, another study
that focused in transplant-free survival in patients with SSc-associated PAH and ILD has already suggested treating that particular group of patients aggressively with prostanoids, even with significant ILD, as they were a protective factor that improved survival ${ }^{38}$.

Therefore, our study results suggest that combination therapy is superior to monotherapy in terms of survival. Appreciably, PAH guidelines have recently included both upfront and sequential combination therapy as first line treatment, some of them with grade of recommendation and evidence $\mathrm{IB}^{17}$. In view of the recently reported evidence, also supported by our own study, we agree that combined therapy should be used as initial therapeutic option in the group of SSc-patients with PAH.

Independent risk factors for mortality in SSc-related PAH have been widely described ${ }^{39-42}$. In our study, the only independent risk factors of mortality were the prescribed treatment regimen and the FC. In multivariate analysis, sequential combination therapy was a long-term protective factor when compared to monotherapy, with a significant decrease of $89 \%$ in mortality. Of major interest, upfront combination therapy also showed a decrease in mortality of $32 \%$, but did not reach statistical significance. These findings did not confirm the idea that initiating upfront combination therapy should give better results than escalating therapy, because different pathways are attacked earlier and their effects may mount. The possible explanation is that our sample size under upfront combination therapy was relatively small and most patients had different baseline characteristics that suggest greater severity, some of them statistically significant, such as higher mPAP, and a tendency to a worse FVC, worse DLco and ratio FVC/DLco, higher systolic pulmonary arterial pressure (sPAP) by
echocardiography, higher TRV, lower tricuspid annular plane systolic excursion (TAPSE) and higher percentage of pericardial effusion.

Other studies included different risk factors in their analyses. We could not analyze all of them given the nature of our study, based in a retrospective database in which all parameters were predetermined so that we could not add new parameters not registered previously in the database. Thus, genetic risk factors associated with poor prognosis were not analyzed in our study because no genetic tests are included in our database. In contrast to other studies ${ }^{43}$, PAP, either by echocardiogram or right heart catheterization was not a risk factor in our study, neither in the univariate nor multivariate analysis. In the previous subgroups analysis of functional, echocardiograph and hemodynamic parameters, sPAP was not statistically different between groups although there were differences and the mPAP was statistically significantly worse in the upfront combination group (perhaps as a reflection of more severe illness). In the risk factor analysis, sPAP showed a trend of higher mortality risk [HR=1.43 (0.94-2.17); $\mathrm{p}=0.095$ )] but not significant and mPAP showed no higher risk. Furthermore, we only checked changes of more than 10 mmHg as a risk factor and the range of PAP in our patients were narrower. Also, the size of the sample could have been a reason for the lack of statistical significance. Time between SSc onset and diagnosis of PAH was neither an independent risk factor in our study, as the univariate Cox's regression results show $\mathrm{HR}=1.03$ ( $95 \% \mathrm{Cl} ; 0.99-1.0$ ), $\mathrm{p}=0.073$. Accordingly to other studies ${ }^{43}$, we did find neither gender, disease subset, right atrial pressure nor change in DLCO or FVC as risk factors for mortality.

In our opinion, the most important strength of the present study is the fact that the investigation only focused on the specific group of SSc-related PAH patients, and evaluated long-term mortality as a single endpoint instead of a combined endpoint of morbidity and mortality.

Our study has several limitations. Firstly, the retrospective design instead of a controlled trial allows us to reach only general conclusions. Secondly, the study sample size, shorter than other PAH studies focused on IPAH, may have limited statistical significance of analyzed prognostic factors. On the other hand, the study sample is relevant enough and representative on our national level to assess long term-mortality in the particular SSc-associated PAH patients.

In conclusion, our study not only confirmed the superiority of combined therapy versus monotherapy on reducing long-term mortality rates in our Spanish nationwide cohort of SSc-PAH patients, but also reaffirmed the better survival of the group of patients treated with sequential combination therapy, even with a mild to moderate degree of ILD. Furthermore, our results also suggest that upfront combination might improve survival as well, without statistical confirmation due to study limitations. Thus, further studies are needed to evaluate the exact role of upfront combination compared to sequential combination, since prognosis of SSc-PAH still remains fatal.

This study was not supported by any kind of funding.

## ACKNOWLEDGEMENTS

We gratefully acknowledge all investigators who form part of the RESCLE Registry. This project was possible thanks to an educational unrestricted scholarship granted by Laboratorios Actelion. We also thank the RESCLE Registry Coordinating Center, S\&H Medical Science Service, for their quality control data, logistic and administrative support and Prof. Salvador Ortiz, Universidad Autónoma de Madrid and Statistical Advisor S\&H Medical Science Service for the statistical analysis of the data presented in this paper. The authors declare that there are no conflicts of interest.

## REFERENCES

1. McGregor AJ, Canavan R, Knight C, Denton CP, Davar J, Coghlan J et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatol 2010; 40: 453-59.
2. Mukerjee D, St George D, Coleiro B, C Knight, Denton CP, Davar J et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003; 62: 1088-93.
3. Wigley FM, Lima JA C, Mayes M, McLain D, Chapin JL, Ward-Able C. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of communitybased rheumatologists (the UNCOVER study). Arthritis Rheumatol 2005; 52: 2125-32.
4. Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter study. Arthritis Rheumatol 2005; 52: 3792800.
5. Coghlan JG, Denton CP, Grünig E, Bonderman D, Distler O, Khanna D et al. on the behalf of the DETECT study group. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 2014; 73: 1340-9.
6. Tyndall AJ, Bannert B, Vonk M, Airò P, Cozzi F, Carreira PE et al. Causes and risk factors for death in systemic sclerosis: a study from EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809-15.
7. Rubio-Rivas M, Royo C, Simeón CP, Corbella X, Fonollosa V. Mortality and survival in systemic sclerosis: systematic review and meta-analysis. Semin Arthritis Rheum 2014; 44: 208-19.
8. Simeón-Aznar CP, Fonollosa-Plá V, Tolosa-Vilella C, Espinosa-Garriga G, Campillo-Grau M, Ramos-Casals M et al. Registry of the Spanish Network for Systemic Sclerosis: Survival, Prognostic Factors, and Causes of Death. Medicine (Baltimore) 2015; 94: 1-9.
9. Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary Hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996; 35: 989-93.
10. Badesch DB, McGoon MD, Barst RJ, Tapson VF, Rubin LJ, Wigley FM et al. Long term survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol. J Rheumatol 2009; 36: 2244-49.
11. Rubenfire M, Huffman MD, Krishnan S, Seibold JR, Schiopu E, McLaughlin VV. Survival in systemic sclerosis with pulmonary arterial hypertension has not improved in the modern era. Chest 2013; 144: 1282-90.
12. Williams MH, Das C, Handler CE, Akram MR, Davar J, Denton CP et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 2006; 92: 926-32.
13. Launay D, Sitbon O, Hachulla E, Mouthon L, Gressin V, Rottat L et al. Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. Ann Rheum Dis 2013; 72: 1940-46.
14. Rubin LJ, Badesch DB, Barst RJ, Galiè N, Black CM, Keogh A et al. for the Bosentan Randomized Trial of Endothelin Receptor Antagonist Therapy study group (BREATHE). N Engl J Med 2002; 346: 896-903.
15. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D et al. for the Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) study group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-57.
16. Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z et al. on behalf of the Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) study group. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894-903.
17. The Joint Task Force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2016; 37: 67-119.
18. Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV et al. for the AMBITION investigators. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015; 373: 834-44.
19. Coghlan JG, Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper M et al. for the AMBITION Investigators. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis 2016; 0: 1-9.
20. Mukerjee D, St George D, Coleiro B, C Knight, Denton CP, Davar J et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003; 62: 1088-93.
21. Fisher MR, Mathai SC, Champion HC, Girgis RE, Housten-Harris T, Hummers Let al. Clinical Differences Between Idiopathic and SclerodermaRelated Pulmonary Hypertension. Arthritis Rheumatol 2006; 54: 3043-50.
22. Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JS R, Vrapi F et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179: 151-57.
23. Hachulla E, Launay D, Mouthon L, Sitbon O, Berezne A, Guillevin L et al. for the French PAH-SSc network. Is pulmonary arterial hypertension really a late complication of systemic sclerosis? Chest 2009; 136: 1211-19.
24. Launay D, Sitbon O, Le Pavec J, Savale L, Tcherakain C, Yaici A et al. Long-term outcome of systemic sclerosis associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatol 2010; 49: 490-500.
25. Chung L, Domsic RT, Lingala B, Alkassab F, Bolster M, Csuka ME et al. Survival and predictors of mortality in systemic-sclerosis associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res 2014; 66: 489-95.
26. Farber HW, Miller DP, Poms AD, Badesch DB, Frost AE, Muros-Le Rouzic E et al. Five-year outcomes of patients enrolled in the REVEAL Registry. Chest 2015; 148: 1043-54.
27. Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J. Goaloriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005; 26: 858-63.
28. Benjamin D. Fox, Avi Shimony and David Langleben. Meta-Analysis of monotherapy versus combination therapy for pulmonary arterial hypertension. Am J Cardiol 2011; 108: 1177-82.
29. Dardi F, Manes A, Palazzini M, Bachetti C, Mazzanti G, Rinaldi A et al. Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights. Eur Respir J 2015; 46: 41421.
30. Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, et al. for the SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension. $N$ Engl J Med 2013; 369: 809-18.
31. McLaughlin V, Channick RN, Ghofrani HA, Lemarié JC, Naeije R, Packer M et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J 2015; 46: 405-13.
32. Lajoie AC, Lauzière G, Lega JC, Lacasse Y, Martin S, Simard S et al. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. Lancet Respir Med 2016; 4: 291-305.
33. Fox BD, Shtraichman O, Langleben D, Shimony A, Kramer MR. Combination therapy for pulmonary arterial hypertension: a systematic review and meta-analysis. Can J Cardiol 2016; 32: 1520-30.
34. Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N et al. for the GRIPHON investigators. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 2015; 373: 2522-33.
35. Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC et al. for the PATENT-1 Study Group. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013; 369: 330-40.
36. Humbert M, Barst RJ, Robbins IM, Channick RN, Galiè N, Boonstra A et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24: 353-59.
37. Lefèvre G, Dauchet L, Hachulla E, Montani D, Sobanski V, Lambert M et al. Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension. A systematic review and meta-analysis. Arthritis Rheum 2013; 65: 2412-23.
38. Volkmann ER, Saggar R, Khanna D, Torres B, Flora A, Yoder L et al. Improved transplant-free survival in patients with systemic sclerosisassociated pulmonary hypertension and interstitial lung disease. Arthritis Rheumatol 2014; 66: 1900-08.
39. Campo A, Mathai SC, Le Pavec J, Zaiman AL, Hummers LK, Boyce D et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med 2010; 182: 252-60.
40. Chung L, Liu J, Parson L, Hassoun PM, McGoon M, Badesch D et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: Identifying systemic sclerosis as a unique phenotype. Chest 2010; 138: 1383-94.
41. Chung L, Farber HW, Benza R, Miller DP, Parsons L, Hassoun PM et al. Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. Chest 2014; 146: 1494-504.
42. Williams MH, Handler CE, Akram R, Smith CJ, Das C, Smee J et al. Role of N-terminal brain natriuretic peptide (NT-proBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 2006; 27:1485-94.
43. Johnson SR, Swiston JR, Granton JT. Prognostic factors for survival in scleroderma associated pulmonary arterial hypertension. J Rheumatol 2008; 35:1584-90.

## FIGURE LEGENDS

Figure 1. Survival among groups from the diagnosis of PAH. Log Rank ratio pvalue $=0.007$.

## APPENDIX

## RESCLE Registry members:

Callejas Moraga E, Carbonell C, Chamorro AJ, Colunga D, Corbella X, Espinosa G, Estévez M, Fernández de la Puebla RA, Fonollosa V, Freire M, Gracia Tello B, Guillén del Castillo A, Iniesta N, Lorenzo R, Madroñero AB, Marín Ballvé A, Ortego-Centeno N, Perales I, Pestaña-Fernández M, Pla Salas X, Pons Martín del Campo I, Rodríguez Carballeira M, Rubio-Rivas M, Ruiz Muñoz M, Salvador G, Segovia P, Simeón CP, Tarí E, Todolí JA, Tolosa C, Trapiella L, Vargas Hitos JA.

Table 1. General features among groups.

|  | Monotherapy | Sequential <br> combination | Upfront <br> combination | Global <br> p-value | Monotherapy <br> vs. <br> sequential $p-$ <br> value | Monotherapy <br> vs. upfront <br> $p-v a l u e ~$ |
| :--- | :---: | :---: | :---: | :---: | :---: | :---: |


| Patients | 34 | 25 | 17 |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Peripheral vascular involvement n(\%) |  |  |  |  |  |  |
| Raynaud's phenomenon | 32 (97) | 22 (88) | 15 (94) | 0.402 | 0.305 | 1.000 |
| Digital ulcers | 14 (42) | 12 (48) | 9 (56) | 0.659 | 0.791 | 0.542 |
| Telangiectasia | 24 (71) | 18 (72) | 12 (75) | 0.949 | 1.000 | 1.000 |
| Acrosteolysis | 1 (5.3) | 3 (23) | 0 | 0.162 | 0.279 | 1.000 |
| Musculoskeletal involvement n (\%) | 14 (41) | 12 (50) | 6 (40) | 0.757 | 0.596 | 1.000 |
| Calcinosis | 7 (21) | 6 (24) | 1 (6.7) | 0.377 | 0.762 | 0.406 |
| Arthritis | 5 (26) | 3 (23) | 1 (14) | 0.812 | 1.000 | 1.000 |
| Myositis | 3 (16) | 3 (23) | 3 (43) | 0.348 | 0.666 | 0.293 |
| Tendon friction rubs | 1 (5.3) | 0 | 0 | 0.583 | 1.000 | 1.000 |
| Joint contractures | 6 (21) | 6 (29) | 4 (27) | 0.837 | 0.739 | 0.719 |
| Digestive involvement n (\%) | 25 (74) | 17 (74) | 12 (75) | 0.994 | 1.000 | 1.000 |
| Esophagus | 22 (65) | 15 (65) | 10 (63) | 0.984 | 1.000 | 1.000 |
| Gastric | 6 (25) | 3 (18) | 3 (25) | 0.837 | 0.711 | 1.000 |
| Intestinal | 4 (17) | 4 (24) | 3 (25) | 0.797 | 0.698 | 0.664 |
| Malabsorption | 4 (17) | 3 (15) | 3 (21) | 0.883 | 1.000 | 1.000 |
| Lung involvement n (\%) | 34 (100) | 25 (100) | 17 (100) | 1.000 | 1.000 | 1.000 |
| ILD | 20 (59) | 20 (80) | 13 (76) | 0.171 | 0.100 | 0.352 |
| Heart involvement n (\%) | 16 (47) | 12 (50) | 5 (31) | 0.468 | 1.000 | 0.365 |
| Pericardial effusion | 9 (26) | 4 (16) | 4 (24) | 0.629 | 0.526 | 1.000 |
| Pericarditis | 2 (5.9) | 3 (12) | 5 (29) | 0.063 | 0.641 | 0.034 |
| Ischemia | 5 (15) | 4 (16) | 1 (5.9) | 0.596 | 1.000 | 0.650 |
| Conduction alteration | 9 (26) | 7 (28) | 2 (12) | 0.419 | 1.000 | 0.297 |
| Diastolic dysfunction | 17 (50) | 10 (40) | 6 (35) | 0.556 | 0.598 | 0.381 |
| Renal involvement n (\%) | 4 (12) | 2 (8.3) | 3 (19) | 0.611 | 1.000 | 0.666 |
| Scleroderma renal crisis | 0 | 0 | 1 (6.3) | 0.159 | 1.000 | 0.320 |
| Cancer n (\%) | 6 (18) | 5 (20) | 4 (24) | 0.883 | 1.000 | 0.714 |
| Capillaroscopy n (\%) | 25 (83) | 19 (83) | 11 (85) | 0.988 | 1.000 | 1.000 |
| Slow pattern | 12 (48) | 9 (47) | 7 (64) | 0.640 | 1.000 | 0.481 |
| Active pattern | 7 (28) | 7 (37) | 3 (27) | 0.786 | 0.745 | 1.000 |
| Normal/undetermined pattern | 6 (24) | 3 (16) | 1 (9.1) | 0.534 | 0.710 | 0.400 |
| Immunological features n (\%) |  |  |  |  |  |  |
| ANA + | 32 (94) | 25 (100) | 17 (100) | 0.281 | 0.503 | 1.000 |
| ATA + | 7 (23) | 2 (8.3) | 3 (19) | 0.367 | 0.271 | 0.753 |
| ACA + | 20 (65) | 11 (48) | 9 (56) | 0.470 | 0.272 | 0.471 |
| Anti-RNA pol III + | 0 | 1 (13) | 1 (13) | 0.543 | 0.471 | 1.000 |
| Anti-RNP + | 1 (3.4) | 1 (4.3) | 0 | 0.701 | 1.000 | 0.714 |

ILD: interstitial lung disease; ATA: Anti-topoisomerase I antibody; ACA: Anti-centromere antibody; AntiRNA pol III: Anti-RNA polymerase III antibody; Anti-RNP: Anti-ribonucleoprotein antibody.

Table 2. Functional class, echocardiography, PFT and hemodynamic parameters at baseline.

|  | Monotherapy | Sequential combination | Upfront combination | Global $p$-value | Monotherapy vs. sequential $p$-value | Monotherapy vs. upfront $p$-value |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Functional class |  |  |  |  |  |  |
| 1 | 6 (18) | 4 (17) | 2 (13) | 0.897 | 1.000 | 1.000 |
| 11 | 9 (26) | 6 (25) | 6 (38) | 0.654 | 1.000 | 0.514 |
| III | 13 (38) | 11 (46) | 8 (50) | 0.701 | 0.598 | 0.543 |
| IV | 2 (5.9) | 1 (4.2) | 0 | 0.616 | 1.000 | 1.000 |
| FVC (\%mean and SD) | $67.6 \pm 19.6$ | $71.7 \pm 22.6$ | $59.7 \pm 23.8$ | 0,500 | 0.661 | 0.403 |
| DLco (\%mean and SD) | $25.3 \pm 13.5$ | $43.6 \pm 18.6$ | $38.1 \pm 16.9$ | 0.183 | 0.080 | 0.218 |
| FEV1 (\%mean and SD) | $63.4 \pm 6.8$ | $63.3 \pm 6.8$ | $64.7 \pm 6.7$ | 0.894 | 0.988 | 0.664 |
| FVC/DLco (mean and SD) | $2.9 \pm 1.1$ | $1.8 \pm 0.4$ | $2.3 \pm 0.8$ | 0.085 | 0.043 | 0.365 |
| sPAP by echocardiography |  |  |  |  |  |  |
| mmHg (mean and SD) | $62.2 \pm 21.5$ | $64.0 \pm 14.3$ | $79.3 \pm 31.9$ | 0.260 | 0.834 | 0.152 |
| TRV m/s (mean and SD) | $3.7 \pm 0.7$ | $3.7 \pm 0.6$ | $3.9 \pm 1.0$ | 0.798 | 0.973 | 0.532 |
| TAPSE mm (mean and SD) | $19.5 \pm 1.3$ | $20.5 \pm 2.1$ | $13.1 \pm 9.6$ | 0.319 | 0.495 | 0.275 |
| Pericardial effusion n (\%) | 3 (19) | 2 (22) | 4 (50) | 0.248 | 1.000 | 0.167 |
| Right ventricular dilation n (\%) | 7 (44) | 5 (56) | 4 (67) | 0.608 | 0.688 | 0.635 |
| mPAP mmHg (mean and SD) | $37.2 \pm 8.7$ | $40.8 \pm 8.8$ | $46.0 \pm 15.9$ | 0.026 | 0.120 | 0,046 |
| PCWP mmHg (mean and SD) | $12.8 \pm 6.2$ | $11.1 \pm 4.1$ | $14.2 \pm 5.0$ | 0.254 | 0.303 | 0.467 |
| Cardiac output litres/minute (mean and SD) | $4.2 \pm 1.3$ | $4.3 \pm 1.7$ | $4.2 \pm 1.7$ | 0.963 | 0.775 | 0.898 |
| PVR Wood units (mean and SD) | $8.2 \pm 5.9$ | $8.1 \pm 3.8$ | $8.3 \pm 4.9$ | 0.994 | 0.947 | 0.966 |

PFT: pulmonary functional tests; FVC: forced vital capacity; SD: standard deviation; DLco: diffusing capacity of the lung for carbon monoxide; FEVI: forced expiratory volume in the first second; sPAP: systolic pulmonary arterial pressure; TRV: tricuspid regurgitation velocity; TAPSE: tricuspid annular plane systolic excursion; mPAP: mean pulmonary arterial pressure; PCWP: pulmonary capillary wedge pressure; PVR: pulmonary vascular resistance.

Table 3. Risk factors associated with mortality.

|  | Univariate Analysis HR (95\%CI) | p-value | Multivariate analysis <br> HR (95\%CI) | p-value |
| :---: | :---: | :---: | :---: | :---: |
| Time onset-diagnosis PAH | 1.03 (0.99-1.07) | 0.073 | - |  |
| Sex (female) | 0.63 (0.24-1.69) | 0.363 | - |  |
| Age per 10-year change | 1.14 (0.76-1.73) | 0.524 | - |  |
| SSc subset (limited+sine scleroderma) | 1.58 (0.66-3.78) | 0.300 | - |  |
| Treatment |  | 0.016 |  | 0.032 |
| Monotherapy | 1 (ref.) | - | 1 (ref.) | - |
| Seqüential combination therapy | 0.20 (0.07-0.61) | 0.004 | 0.23 (0.07-0.69) | 0.009 |
| Upfront combination therapy | 0.59 (0.22-1.60) | 0.302 | 0.72 (0.25-2.07) | 0.541 |
| Functional class |  | 0.003 |  | 0.007 |
| I | 1 (ref.) | - | 1 (ref.) | - |
| II | 1.00 (0.32-3.09) | 0.994 | 1.20 (0.37-3.87) | 0.765 |
| III | 1.04 (0.38-2.80) | 0.943 | 1.24 (0.45-3.39) | 0.675 |
| IV | 12.93 (2.90-57.62) | 0.001 | 12.18 (2.71-54.69) | 0.001 |
| FVC per 10\% of predicted change | 0.86 (0.64-1.16) | 0.316 | - |  |
| DLco per 10\% of predicted change | 0.25 (0.05-1.13) | 0.071 | - |  |
| FVC/DLco per 10\% of predicted change | 683.65 (1.89-24750897) | 0.030 | - |  |
| sPAP per ECO per $10-\mathrm{mmHg}$ change | 1.43 (0.94-2.17) | 0.095 | - |  |
| VRT per $1 \mathrm{~m} / \mathrm{s}$ change | 9.36 (1.74-50.34) | 0.009 | - |  |
| TAPSE per $10-\mathrm{mm}$ change | 0.17 (0.02-1.23) | 0.078 | - |  |
| Pericardial effusion | 1.64 (0.50-5.38) | 0.417 | - |  |
| Right ventricular dilation | 2.10 (0.63-7.01) | 0.226 | - |  |
| mPAP | 1.02 (0.99-1.05) | 0.242 | - |  |
| RAP | 1.00 (0.86-1.16) | 0.995 | - |  |

HR: hazard ratio; DcSSc: diffuse cutaneous Systemic sclerosis; FVC: forced vital capacity; DLco: diffusing capacity of the lung for carbon monoxide; sPAP: systolic pulmonary arterial pressure; mPAP: mean pulmonary arterial pressure; RHC: right heart catheterization; TRV: tricuspid regurgitation velocity; TAPSE: tricuspid annular plane systolic excursion; RAP: right atrial pressure.

Table 4. Survival and patients at risk among groups from the diagnosis of PAH.

| Survival | 4 weeks | 26 weeks | 52 weeks | 04 weeks | 156 weeks |
| :--- | :---: | :---: | :---: | :---: | :---: |
| Monotherapy | 0.970 | 0.878 | 0.780 | 0.645 | 0.407 |
| Sequential combined therapy | 1.000 | 0.958 | 0.958 | 0.958 | 0.815 |
| Upfront combined therapy | 1.000 | 0.941 | 0.941 | 0.776 | 0.518 |


| Patients on risk | $0-4$ weeks | $4-26$ | weeks | $26-52$ weeks | $52-104$ weeks | $104-156$ weeks |
| :--- | :---: | :---: | :---: | :---: | :---: | :---: |
| Monotherapy | 33 | 31 | 27 | 23 | 17 |  |
| Sequential combined therapy | 25 | 25 | 23 | 22 | 20 |  |
| Upfront combined therapy | 17 | 17 | 14 | 12 | 7 |  |

Table 5. Causes of death.

|  | Monotherapy | Sequential <br> combination | Upfront combination | Global <br> p-value |
| :--- | :---: | :---: | :---: | :---: |
| ILD | $2(11.8 \%)$ | 0 | 0 | 0.564 |
| PAH | $7(41.2 \%)$ | $2(50 \%)$ | $3(60 \%)$ | 0.749 |
| PAH+ILD | $1(5.9 \%)$ | $0(0 \%)$ | 0 | 0.759 |
| Neoplasm | $2(11.8 \%)$ | $1(25 \%)$ | 0 | 0.506 |
| Ischaemic myocardiopathy | $1(5.9 \%)$ | 0 | 0 | 0.759 |
| Sepsis | $1(5.9 \%)$ | 0 | $1(20 \%)$ | 0.759 |
| Heart failure | 0 | $1(25 \%)$ | $1(20 \%)$ | 0.645 |
| Others | $0(17.6 \%)$ | 0 | 5 | 0.124 |
| Total deaths | 17 | 4 | 0 |  |

ILD: Interstitial lung disease; PAH: pulmonary arterial hypertension.


Survival among groups from the diagnosis of PAH. Log Rank ratio p-value=0.007.

$$
133 \times 106 \mathrm{~mm}(120 \times 120 \mathrm{DPI})
$$

